- Specialization
- Biotechnology
- Business
- Scientific Research
- Market
- Life Sciences
- Ecosystem
- Not applicable
- Customers
- Consumers
More details
- Organization type
- Commercial Company
- Ecosystem
- Not applicable
- Business
- Scientific Research
- Specialization
- Biotechnology
- Market
- Life Sciences
- Customers
- Consumers
- Delivery models
- Not classified
- Revenue models
- Not classified
- Listing status
- Not classified
- Latest equity round
- Not classified
- Reported funding amount
- Not classified
About
Guardian Bio develops personalized dendritic-cell therapies for late-stage solid-tumor cancer patients. Its proprietary process generates true cDC1 cells from a patient’s own stem cells, creating Guard-cDC1s designed to restore dysfunctional antigen presentation and activate multiple immune effectors.
Market
Guardian Bio competes in oncology immunotherapy, particularly personalized cell-based cancer vaccines and dendritic-cell therapies for late-stage solid tumors. Its differentiation is a proprietary process for generating true cDC1s from a patient’s own stem cells, programming them against multiple tumor targets, and activating diverse immune effectors with selective tumor killing and limited off-target activity; Northwest Biotherapeutics, Diakonos, Mendus, and Dendreon are the closest dendritic-cell comparables, while Candel and Elicio are adjacent cancer-vaccine competitors.
Guardian Bio primarily targets late-stage solid-tumor cancer patients, initially including subsets of head-and-neck, breast, and lung cancer, with oncologists and specialist cancer centers as the key clinical decision-makers. On the business side, it is an early-stage biotech platform likely oriented toward oncology clinical-development organizations and research partners; the evidence does not specify a target partner-company size.
At a Glance
Problem
Guardian Bio is addressing a biological bottleneck in late-stage solid-tumor cancer: cancer can disable dendritic cells, the immune cells responsible for presenting tumor antigens and directing anti-cancer responses. When this system is deficient or dysfunctional, patients may have limited ability to fight cancer even with chemotherapy or immunotherapy. The company’s main use case is therefore to restore anti-cancer immunity in patients whose advanced solid tumors have evaded existing immune defenses. The economic pain is not quantified publicly, but the implied value is extending effective treatment to patients who otherwise may not respond to current therapies.
Product / Service
Guardian Bio is developing a personalized, cell-based cancer immunotherapy. Its process takes stem cells from an individual cancer patient, differentiates them into a specific dendritic-cell population called cDC1s, programs the cells against that patient’s tumor, and reinfuses them. The company calls these engineered cells Guard-cDC1s, designed to restore antigen presentation and activate multiple immune effector cells against several cancer targets at once.
The intended benefit is a targeted but broad immune response with less off-target killing than nonspecific approaches. Guardian Bio reports that its platform has selectively activated killer T-cell populations against multiple targets, including material from late-stage cancer patients, and that it may work synergistically with checkpoint inhibitors, peptide and mRNA vaccines, and oncolytic viruses.
Market
Guardian Bio competes in biotechnology’s personalized cell-therapy, dendritic-cell cancer-vaccine, and broader solid-tumor immunotherapy markets. A close comparator is Immunomic Therapeutics: its ITI-1000 is also an autologous dendritic-cell therapy, although it uses dendritic cells loaded with mRNA. Guardian Bio is differentiated by generating what it describes as true cDC1s from the patient’s own stem cells and training them against multiple tumor targets; adjacent competition includes checkpoint inhibitors, other cancer vaccines, and oncolytic viruses.
The company appears to remain early stage rather than commercially validated. Guardian Bio was founded in 2022, is listed by Y Combinator as active with a small team, and has publicly reported platform-level laboratory evidence, including activity in late-stage patient material. Available financing profiles identify a $500,000 pre-seed round in August 2022, while the available company profile does not disclose a revenue figure; no clear evidence of commercial revenue or an approved product was found in the reviewed sources.
Founders & Leadership
Funding History
Y Combinator
Recent News
VibeCrowd.fund added a profile for Guardian Bio describing it as a biotechnology company developing dendritic-cell therapy for patients with late-stage solid tumors. The profile says Guardian Bio aims to combine regenerative medicine with immunotherapy and address cancer-related dysfunction in cDC1 immune cells.
MassLive reported that Ananya Zutshi, Guardian Bio’s co-founder and CEO, had placed the company in “hibernation” amid a difficult biotech funding environment. The article explained that Guardian Bio had stopped developing its own products and technologies, reduced expenses and staffing, and focused on licensing its patents.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
Guardian Bio has not disclosed commercial pricing, product sales, licensing revenue, or a recurring revenue model. Available evidence indicates that it is an early-stage therapeutics company financed through fundraising while developing its proprietary cell-therapy platform for eventual clinical and commercial use.